Key result
sPLA2-II acts as an inflammatory mediator driving atherosclerosis and ischemic damage in acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
Inflammatory reactions contribute to the pathogenesis of cardiovascular conditions such as atherosclerosis and ischemic damage in acute myocardial infarction (AMI). Among the mediators involved in inflammation are secretory phospholipase A2 group II (sPLA2-II) enzymes. Though some cells constitutively express sPLA2-II, the synthesis by cells such as hepatocytes is typical for an acute-phase reactant. Recent literature suggests multiple roles for sPLA2-II in cardiovascular disease. In this review we discuss the role of sPLA2-II in various in vivo and in vitro models of atherosclerosis or AMI, including the therapeutic perspective of sPLA2-II inhibitors. It was concluded that sPLA2-II appears to be an important inflammatory mediator of cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Hans W.M. Niessen (2003) conducted a review in Cardiovascular disease, atherosclerosis, and acute myocardial infarction. Secretory phospholipase A2 group II (sPLA2-II) and sPLA2-II inhibitors was evaluated. Secretory phospholipase A2 group II (sPLA2-II) appears to be an important inflammatory mediator of atherosclerosis and ischemic damage in acute myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: